ORIGINAL RESEARCH article
Front. Public Health
Sec. Public Health Policy
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1576527
This article is part of the Research TopicHealth Policy Approaches to Chronic Disease ManagementView all 5 articles
Global, Regional, and National Burden of Gastroesophageal Reflux Disease (1990-2021): Age-Period-Cohort Analysis and Bayesian Projections
Provisionally accepted
- 1Foshan Women and Children Hospital, Foshan, Guangdong Province, China
- 2Pingxiang People's Hospital, Pingxiang, China
- 3Shunde Hospital, Southern Medical University, Foshan, Guangdong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Gastroesophageal reflux disease (GERD) is a common chronic upper gastrointestinal disorder that causes discomfort and increases the risk of esophageal adenocarcinoma. The global burden of GERD has steadily increased, establishing it as a critical public health issue. This study systematically evaluated the global, regional, and national burden of GERD from 1990 to 2021, revealing epidemiological trends and regional disparities to inform targeted intervention strategies.Methods: We utilized data from the 2021 Global Burden of Disease Study (GBD) to assess the prevalence, incidence, and years lived with disability (YLDs) of GERD. Key indicators included age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized YLDs rate (ASYR), and estimated annual percentage change (EAPC). Analyses were stratified by age, gender, and socio-demographic index (SDI). Age-period-cohort (APC) models were applied to examine trends in the 15–49 age group, and Bayesian APC models were used to project future trends.Results: In 2021, global GERD prevalence reached 825.6 million (95% uncertainty interval: 732.99–925.56 million). From 1990 to 2021, incident cases, prevalent cases, and YLDs rose by 83.16%, 80.06%, and 82.46%, respectively. The ASIR, ASPR, and ASYR all showed upward trends, with EAPCs of 0.097, 0.076, and 0.083. The highest burden of ASIR, ASPR, and ASYR was observed in Tropical Latin America in 2021, while the lowest was in East Asia. Regions with lower SDI had higher ASIR, ASPR, and ASYR. In the 15-49 age group, the GERD burden increased with age across all SDI regions, with unfavorable period effects observed in high and high-middle SDI regions, as well as adverse cohort effects in high-middle and middle SDI regions. Projections indicate that by 2035, global GERD cases in this age group will reach 527.2 million (ASPR: 12,082.06/100,000), with 214.6 million incident cases (ASIR: 4,916.68/100,000) and 4.1 million YLDs (ASYR: 94.47/100,000).Conclusions: GERD poses a growing global health challenge. Insights from these observed epidemiological patterns can assist policymakers in developing targeted measures to reduce its impact, particularly in high-risk regions and younger demographics.
Keywords: Gastroesophageal reflux disease, GBD, Age-standardized rate, age-periodcohort, Bayesian projections
Received: 14 Feb 2025; Accepted: 26 Jun 2025.
Copyright: © 2025 Mo, Liu, Cao, Gong, Wu, Lin and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Pan, Foshan Women and Children Hospital, Foshan, 528000, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.